Drug guide · evidence, not hype
Mounjaro
tirzepatide · a dual GLP-1 and GIP receptor agonist · made by Eli Lilly
Mounjaro is the type 2 diabetes brand of tirzepatide — a dual-agonist that acts on two gut hormones, not one. Its weight-management twin is Zepbound: same molecule, different label.
The short answer
Mounjaro is a brand name for tirzepatide, a dual GLP-1 and GIP receptor agonist made by Eli Lilly and FDA-approved for type 2 diabetes. Unlike semaglutide (Ozempic/Wegovy), which targets one gut-hormone receptor, tirzepatide targets two. It is the same molecule as Zepbound, which carries the chronic-weight-management and obstructive-sleep-apnea indications.
- Molecule
- tirzepatide
- How it works
- a dual GLP-1 and GIP receptor agonist
- Maker
- Eli Lilly
- Form
- a once-weekly injection
- FDA-approved for
- type 2 diabetes
- Sibling brand
- Zepbound — the same molecule, approved for weight management and sleep apnea
No doses, no sourcing. This page explains what Mounjaro is and points you to graded answers — it doesn’t recommend a product, a dose, or a place to buy anything.
Same molecule, different brand
Mounjaro is tirzepatide. Here is how tirzepatide maps to its approved brands — Zepbound is its sibling (the same molecule, approved for weight management and sleep apnea).
What each brand is approved for
| Brand | Molecule | Type 2 diabetes | Weight management | Cardiovascular risk | Obstructive sleep apnea |
|---|---|---|---|---|---|
| Mounjaro | tirzepatide | ✓ | — | — | — |
| Ozempic | semaglutide | ✓ | — | ✓* | — |
| Wegovy | semaglutide | — | ✓ | ✓* | — |
| Zepbound | tirzepatide | — | ✓ | — | ✓ |
✓ FDA-approved · ✓* approved in a defined sub-population (e.g. cardiovascular-risk reduction requires established heart disease). From each product’s FDA label. Not medical advice, not a buying guide.
Start here
The questions people actually ask about Mounjaro — each answered on the site’s 8-rung Evidence Ladder and linked to primary sources.
- Rung 1Mounjaro vs. Zepbound: same molecule, two different labelsSame molecule, two brands — Mounjaro vs Zepbound, explained.
- Rung 1Tirzepatide side effects: what the evidence actually showsWhat the evidence shows about tirzepatide’s side effects.
- Rung 1Semaglutide vs tirzepatide: how they really compareHow the dual-agonist compares with semaglutide.
- Rung 2Can a GLP-1 treat fatty liver disease (MASH)?The fatty-liver (MASH) question people ask about tirzepatide.
- Rung 1Ozempic vs Wegovy vs Mounjaro vs Zepbound: the brand decoderThe full four-brand, two-molecule map.
- Rung 1GLP-1 cost and access in 2026: how pricing and coverage workHow pricing and coverage actually work in 2026.
Myths about Mounjaro, graded
The viral claims, checked against the evidence — not a true/false binary, but how much weight the evidence can actually bear.
- Strong evidenceRung 1 of 8 · Established“Zepbound and Mounjaro are different drugs.”Same molecule — both are tirzepatide; the two brands exist because the drug is approved (and marketed) for different uses.
- Strong evidenceRung 1 of 8 · Established“Tirzepatide is just a stronger version of Ozempic.”Partly true, oversimplified
- Strong evidenceRung 1 of 8 · Established“Tirzepatide (Mounjaro/Zepbound) is FDA-approved to treat fatty liver disease (MASH).”False — semaglutide (Wegovy) is the GLP-1 approved for MASH; tirzepatide isn't (still investigational).
- Strong evidenceRung 2 of 8 · Supported but limited“GLP-1s paralyze your stomach and give you gastroparesis.”Partly true, oversimplified
- Limited evidenceRung 4 of 8 · Observational only“GLP-1s cause thyroid cancer.”Misleading overstatement
Free, private tools
Everything runs on your device and stores nothing on our servers.
Sources
Every claim on this page traces to a primary source — and we sell you nothing. No sponsors, no affiliate links, no ads.
- 2 FDA labels